Welcome to our dedicated page for Metsera SEC filings (Ticker: MTSR), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Dissecting Metsera’s latest 10-K means navigating dense peptide-science jargon, clinical trial updates and milestone-based collaboration clauses that can stretch to 250 pages. If you have ever searched “Metsera SEC filings explained simply,” you know how long it takes to locate cost-of-goods data for its NuSH analog pipeline or risk factors tied to lipid-optimization patents. Investors also wrestle with tracking “Metsera insider trading Form 4 transactions” around Phase 2 data releases. Stock Titan resolves these headaches by delivering AI-powered summaries that surface trial timelines, cash-burn trends and research commitments in seconds—no more hunting through footnotes.
Every disclosure streams into one dashboard the moment it hits EDGAR. Need the “Metsera quarterly earnings report 10-Q filing” before tomorrow’s call? Our system posts it within minutes and adds a concise Metsera earnings report filing analysis that highlights progress on MINT-library candidates. Curious about management moves? Receive “Metsera Form 4 insider transactions real-time,” including a breakdown of Metsera executive stock transactions Form 4 versus historical buying patterns. For major announcements, you’ll see “Metsera 8-K material events explained,” complete with plain-language context on clinical setbacks or FDA fast-track wins.
Long-term investors rely on our interpretations that link each filing type to Metsera’s science-driven strategy. The “Metsera annual report 10-K simplified” exposes year-over-year R&D spend and half-life extension milestones, while “Metsera proxy statement executive compensation” uncovers how bonus targets align with trial enrollment metrics. understanding Metsera SEC documents with AI means you can compare capital needs, monitor safety-signal disclosures and forecast dilution risk—without reading every page. From clinical-stage volatility to commercialization planning, Stock Titan keeps you prepared with comprehensive coverage, real-time alerts and expert commentary built for biotech complexity.
Metsera, Inc. (MTSR) reported insider transactions tied to its merger with Pfizer. On 11/13/2025, each share of Metsera common stock was converted into the right to receive $65.60 in cash per share plus one contingent value right (CVR) under the merger terms.
The Chief Medical Officer reported disposition of 17,000 common shares, leaving 0 shares beneficially owned. Outstanding stock options were canceled for cash based on the $65.60 closing amount and CVRs per share covered, including options over 120,000 shares (exercise price $29.25) and options over 829,885 and 21,279 shares (exercise price $0.26). RSUs were also canceled and converted into cash based on the closing amount and an equivalent number of CVRs, with vesting terms preserved under the agreement.
Metsera (MTSR) filed a Form 4 tied to its merger with Pfizer. The filing states each Metsera common share was converted into $65.60 in cash plus one contingent value right (CVR) at closing. The reporting director recorded merger-related dispositions of common stock and the cancellation of equity awards in exchange for the cash consideration and CVRs.
On 11/13/2025, outstanding stock options were canceled for cash (based on the $65.60 closing amount minus the exercise price) and CVRs; RSUs were canceled for cash at $65.60 per underlying share and CVRs. The table shows 4,031 RSUs, and stock options covering 24,188 and 223,430 shares, all settled, with reported post‑transaction holdings shown as zero in the listed entries.
Metsera, Inc. (MTSR) filed a Form 4 for its Chief Legal Officer detailing equity conversions arising from the closing of its merger with Pfizer. At the effective time, each common share converted into $65.60 in cash per share plus one contingent value right (CVR) tied to specified milestones.
The filing reports the disposition of 12,500 shares of common stock, leaving 0 shares beneficially owned. It also shows 12,500 RSUs subject to conversion into cash at the $65.60 closing amount per underlying share plus CVRs, following their original vesting schedule. In addition, stock options for 46,875 shares (exercise price $29.25) and 325,000 shares (exercise price $17.16) were canceled and exchanged for cash equal to the in-the-money value based on the $65.60 closing amount, plus CVRs per underlying share. Unvested awards maintain vesting terms, with merger-related vesting described to occur by the first anniversary, subject to continued service.
Metsera, Inc. (MTSR) reported insider transactions on Form 4 tied to its merger closing with Pfizer on 11/13/2025. At the effective time, each issued and outstanding Metsera common share was converted into the right to receive $65.60 in cash per share, plus one contingent value right (CVR) payable upon specified milestones.
The filing lists holdings associated with Population Health Partners: 12,639,787 shares recorded by Population Health Partners, L.P. and 127,675 shares recorded by Population Health Partners GP, LLC. Following the reported transaction, the filing shows 0 shares beneficially owned by the reporting person.
Metsera (MTSR)Pfizer effective on
Equity awards were also settled under the merger terms. Outstanding stock options were canceled for a cash payment equal to the excess of
Metsera, Inc. (MTSR): Validae Health, L.P. filed a Form 4 reporting a Code J transaction involving the distribution of 12,767,462 shares of Metsera common stock at $0 on November 11, 2025. Following the transaction, the filer reported 0 shares directly owned.
Footnotes state Validae distributed 99% of its Metsera shares to Population Health Partners, L.P. and 1% to Population Health Partners GP, LLC. PHP GP LLC may be deemed to beneficially own shares held by Validae and PHP LP; certain individuals are members of PHP GP LLC and may share dispositive and voting power, with beneficial ownership disclaimed except to the extent of pecuniary interest.
Metsera (MTSR) filed a Form 4 reflecting transactions tied to its merger with Pfizer. At closing, each share of Metsera common stock converted into the right to receive $65.60 in cash per share plus one contingent value right (CVR), per the merger terms.
The reporting person recorded an acquisition of 2,688 RSUs on November 12, 2025, which were then canceled and converted into cash at the Closing Amount and an equal number of CVRs. Outstanding stock options were canceled in exchange for cash equal to intrinsic value and one CVR per underlying share; unvested awards follow prior schedules with vesting on the first merger anniversary subject to continued service. Following these transactions, the Form 4 shows 0 shares of common stock beneficially owned.
Metsera, Inc. (MTSR) filed a Form 4 reflecting transactions tied to its merger with Pfizer Inc.. At the merger’s Effective Time, each share of Metsera common stock was converted into the right to receive $65.60 in cash per share, plus one contingent value right (CVR) payable in cash upon specified milestones.
The reporting person’s holdings changed accordingly: 2,688 shares of common stock were disposed, leaving 0 shares beneficially owned. A restricted stock unit grant of 2,688 RSUs was reported; under the merger, RSUs were canceled and converted into cash equal to the cash amount per share times the RSU count and CVRs equal to the underlying shares, with these payments not subject to vesting. A stock option for 47,730 shares at $19.81 was canceled and exchanged for cash based on the excess of the cash amount over the exercise price, plus one CVR per underlying share. For unvested options, the cash and CVRs will vest on the first anniversary of closing, contingent on continued service.
Metsera, Inc. (MTSR) filed a Form 4 detailing insider transactions tied to its merger with Pfizer. The filing states each share of common stock was converted into the right to receive $65.60 per share plus one contingent value right (CVR).
Chief Scientific Officer Brian Hubbard reported the disposal of 17,000 shares, with 0 shares owned afterward. Outstanding stock options were cancelled for cash equal to any in‑the‑money value plus CVRs, including options covering 319,186 shares at $0.26, 120,000 at $29.25, and 106,395 at $8.18. A grant of 17,000 RSUs on November 12, 2025 was converted to cash at the Closing Amount and CVRs. Unvested cash and CVR amounts vest on the first anniversary of the merger.
Metsera (MTSR) CFO filed a Form 4 detailing equity conversion and cancellation tied to the Pfizer merger. At closing, each Metsera common share was converted into the right to receive $65.60 in cash per share plus one contingent value right (CVR), as described in the merger terms.
The filing shows disposition of 21,250 shares of common stock, leaving 0 shares beneficially owned after the transaction. It also records the award and conversion of 21,250 RSUs, which became the right to receive cash based on $65.60 per underlying share and an equal number of CVRs, subject to the original vesting schedule. All stock options were canceled in exchange for cash equal to any in-the-money value plus one CVR per underlying share, including grants for 150,000 options at $29.25, 255,349 at $4.33, and 340,465 at $8.18, each with 0 remaining after the merger mechanics.
FAQ
What is the current stock price of Metsera (MTSR)?
What is the market cap of Metsera (MTSR)?
